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 ABBREVIATION 
BP  Blood Pressure 
TOD  Target Organ Damage 
JNC  Joint National Committee 
HTN  Hypertension 
MI  Myocardial Infarction 
CVA  Cerebro Vascular Accident 
CAD  Coronary Artery Disease 
OCP  Oral Contraceptive Pills 
HRT  Hormone Replacement Therapy 
NO  Nitric Oxide 
HMW  High Molecular Weight 
DCT  Distal Convoluted Tubule 
LVH  Left Ventricular Hypertrophy 
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INTRODUCTION 
Hypertension is one of the most common cardiovascular 
disorders and it is an emerging health problem in India. When 
people come to know that they have hypertension most of them 
have already progressed into severe stage with target organ 
damage- a fatal stroke or myocardial infarction or irreversible 
renal failure.  
Unfortunately even in developed countries like Unites States 
30% of hypertensives are unaware of its presence in them. Only 
59% of known hypertensives are on treatment and only 34% have 
good control of their  blood  pressure. 
The cost effectiveness of BP reduction with drugs will be 
greater in the presence of target organ damage. In this context 
assessment of subclinical TOD has become the key element in 
evaluating hypertensive patients to prevent further damage. Micro 
albuminuria is one of the earliest indicators of TOD in 
hypertensives. 
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Micro albuminuria reflects vascular damage and appears to 
be a marker of early arterial disease and endothelial dysfunction. 
So early screening of hypertensives for microalbuminuria 
and prompt treatment of positive cases will reduce the target organ 
damage and cardiovascular morbidity in the community. 
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AIMS & OBJECTIVES 
-To find out the prevalence of microalbuminuria in patients 
with Primary Hypertension. 
-To assess the relationship of the microalbuminuria with 
duration, severity  of  Hypertension and previous treatment. 
-To find out the relationship of microalbuminuria with TOD 
in patients with Primary Hypertension like LVH, Stroke and 
Retinopathy 
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REVIEW OF LITERATURE 
PRIMARY HYPERTENSION 
Definition of Hypertension: 
The simplest and most widely accepted definition of 
hypertension in an adult is that hypertension is present when clinic 
systolic BP exceeds 140 mmHg or clinic diastolic BP exceeds 90 
mmHg. The patients with blood pressure more than 140/90 and 
without any secondary demonstrable causes of elevated blood 
pressure are called as primary or essential hypertensives. 
The JNC-7 definition of hypertension reproduced in the 
following table gives a more detailed classification of blood 
pressure for adults aged over 18 years. 
Classification of Blood Pressure for adults ages 18 yrs and older * 
Category Blood Pressure (mmHg) 
Systolic Diastolic 
Optimal < 120 < 80 
Pre hypertension 120 -139 80 -89 
Hypertension +   
Stage 1 140- 159 90-99 
Stage 2 > 160 > 100 
* Not taking antihypertensive drugs and not acutely ill. 
+ based on the average of two or more readings taken at each 
of two or more visits after initial screening. 
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Prevalence: 
On a global level, hypertension is a greater problem, with 
13.5% of all deaths attributed to BP related diseases. A majority of 
those who carry this disease burden belong to lower economic 
strata. 
Hypertension is reported to be the fourth contributor to 
premature death in developed countries and the seventh in 
developing countries. (Mohan V et al, 2003) .Recent reports 
indicate that nearly 1 billion adults (more than quarter of the world 
population) had hypertension in 2000, and this is predicted to 
increase to 1.56 billion by 2025. (Kearney PM et al, 2005) Earlier 
reports also suggest that the prevalence of hypertension is rapidly 
increasing in developing countries and is one of the the leading 
causes of death and disability in them. 
The prevalence of HTN depends on both the racial 
compositions of the population studied and the criteria used to 
define the condition. The prevalence of HTN among blacks is 
greater at every age beyond adolescence and they have a greater 
proportion of more severe disease with higher mortality rate than 
whites  at  every level of outcome (Burt VL et al, 1995). 
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Indian Scenario: 
The Jaipur Heart watch study (Gupta R et al, 2002) and the 
Chennai Urban Rural Epidemiology Study (CURES) reported the 
prevalence and hypertension to be 37% and 20% using the JNC-VII 
guidelines. 
Data of study by Yadav et al suggested that the prevalence of 
hypertension in the younger age group (30-39 years) was 13.7% and 
increased to a peak of 64% in the age group 60-69 years while 
prevalence of pre- hypertension was highest in the age group 30-39 
years (36%). A similar prevalence of pre hypertension in the same 
age group (35.4%) has been reported in Chennai population  
(Mohan V ,et al). 
The prevalence of hypertension will increase even further 
unless broad and effective prevalence measures are implemented at 
this stage as India is a vast country with a heterogenous and young 
population.As rightly commented by Joshi & Parikh, with current 
rate of hypertension India will have the largest number of people  
with hypertension in the world, with the potential of becoming 
the“Hypertension capital of the world “(Joshi SR et al, 2007). 
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Likely Benefits of Treatment: 
The relative risk of high BP for M.I & CVA is higher among 
younger subjects and decreases with age. Absolute risk, by contrast 
increase with age. This means that attributable risk, which is the no 
of events that would be avoided if BP were lower, is likely to be 
higher in the elderly. The attributable risk of diastolic BP for CAD 
is likely to be great because coronary artery disease is more 
common than stroke in  most  western populations. 
Gender Differences: 
Hypertension is an important risk factor for cardiovascular 
disease in women. Although premenopausal women have lower BP 
than age matched men the prevalence of HT is higher in women 
than men after the age of 65. Obesity is significantly more common 
in middle aged and older women and is likely to contribute to cross 
over in prevalence. OCP increases the risk of HT is younger 
women.  
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HRT does not raise the BP in women who are normotensive at 
the start of treatment. The ratio of hypertension frequency in 
women versus men increase from 0.6 to 0.7 at age 30 to 1.1 to 1.2 at age 
65 yrs. 
Complications of Hypertension: 
The higher the level of the blood pressure, the more likely 
that various cardiovascular disease will develop prematurely 
through acceleration of atherosclerosis, the pathological hall mark 
of uncontrolled hypertension. In untreated, about 50% of 
hypertensive patients die of CAD or congestive failure about 33% 
of stroke and 10 - 15% of renal failure. 
In general the vascular complications of hypertension can be 
considered as either hypertensive or atherosclerotic. 
I. Hypertensive complications 
1) Accelerated malignant phase 
2) Hemorrhagic stroke 
3) Congestive heart failure 
4) Nephrosclerosis 
5) Aortic dissection 
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II. Atherosclerotic complications: 
1) Coronary artery disease 
2) Sudden death 
3) Arrhythmias 
4) Atherothrombotic stroke 
5) Peripheral vascular disease 
Aetiopathogenesis of Primary Hypertension 
This can be described under the following headings 
1.   Non renal factors. 
2.  Renal factors 
I.Non - Renal Factors: 
Primary Hypertension is a complex multifactorial and 
polygenic disorder that results from an interaction between an 
individual's genetic back ground and various environmental factors. 
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1.Genetic Predisposition: 
The genetic contributions in the etiopathogenesis of primary 
HT have been estimated to range from 30% to 60%. Harrap 
suggested that "the average population blood pressure is determined 
by environment but the blood pressure rank within the distribution 
is decided largely by genes”. (Harrap, 1994) 
Epidemiological data suggest that for population variability 
in blood pressure genetic factors contribute 30 - 35%, common 
household environment about 10 - 15% and non familial factors for 
the remaining 50 - 55%. (Samani N.J., 2003 ) 
If genetic markers of a predisposition for the development of 
hypertension are found, specific environmental manipulations could then 
be directed toward susceptible subjects. (Pratt R E, Dzau VI, 1999). 
Pratt, from his observation of bimodal distribution of blood 
pressure in some families with hypertensive subjects proposed 
autosomal dominant mode of inheritance. Pickering proposed that 
blood pressure is a quantitative trait with genetic contribution 
which is polygenic. 
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Genome wide scanning strategy in sib-pairs has identified 
chromosomal regions on chr 6, 15, 5 and 12 which showed 
significant linkage to genes that influence interindividual blood 
pressure variation. There are several candidate genes within the 
identified group. (Dominiazek AF, Negrin DC, Clark JS el al, 2000). 
Polymorphism of genes involving the RAS system, 
aldosterone synthesis and adrenergic receptors has been noted to be 
more  common  in  hypertensive  than  normotensive patients. 
The rare forms of hypertension by a monogenic abnormality are 
1) Glucocorticoid remediable aldosteronism 
2) Liddle syndrome 
3) Apparent mineralocorticoid excess 
2.The Fetal Environment: 
Low birth weight as a consequence of fetal under nutrition is 
followed by an increased incidence of high blood pressure later in 
life. Brenner and Cheriow hypothesized that a decreased number of 
nephrons from intrauterine growth retardation could very well serve 
as this permanent, irreparable defect that eventuates in 
hypertension. 
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3. Vascular Remodelling: 
Folkow hypothesized that, in the pathogenesis of primary 
hypertension, .various neurohumoral factors initially increase the 
peripheral vascular resistance but perpetuation of hypertension 
involves vascular remodelling mainly by vascular hypertrophy. 
This vascular hypertrophy may be further reinforced by defects in 
vascular cell membrane and various trophic mechanisms. 
4. Neurohumoral Causes of Primary Hypertension: 
A large number of circulating hormones and locally acting 
substances may be involved in the development of hypertension. 
a) Sympathetic nervous hyperactivity: 
Young hypertensives tend to have increased levels of 
circulating catecholamines, augmented sympathetic nerve traffic in 
muscles, faster heart rate and heightened vascular reactivity to 
adrenergic agonists. (Kim J-R, Kiefe CI, Liu K, el al, 1999) 
These changes could raise blood pressure in a number of 
ways - either alone or in concert with stimulation of renin release 
by catecholamines by causing arteriolar and venous constriction or 
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by increasing cardiac output or by alter the normal renal pressure - 
volume relationship. 
b) Renin - Angiotensin system: 
Both as a direct pressor and as a growth promoter the renin 
angiotensin mechanism may also be involved in the pathogenesis of 
hypertension. This system is the primary stimulus for the secretion 
of aldosterone and hence mediates mineralocorticoid responses to 
varying sodium intake and volume load. 
When large populations of hypertensives are surveyed, only 
about 30 percent have low PRA, where as 50 percent have normal 
levels and the remaining 20 percent have high levels. (Brunner HR, 
Sealey JE, Laragh JK, et al 1973). 
Normal & high renin hypertension: 
Some persons with primary hypertension have normal or high 
renin levels. The concept of "Nephron heterogeneity" described by 
Sealey and colleagues, which assumes a mixture of normal and 
ischemic nephrons caused by afferent arteriolar narrowing. Excess 
renin from the ischemic nephrons could raise the total blood renin 
level. 
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c) Hyper insulinemia / insulin resistance: 
An association between hypertension and hyper insulinemia 
has been recognised for many years, particularly with 
accompanying obesity but also in non obese hypertensives. (Liese 
AD, Mayer - Davis EJ, Haffner SM 1998 ). This association does 
not apply to pima Indians but it has been found in blacks, Asians 
and as well as whites. The impairment of the peripheral actions of 
the insulin resulting from a defect in the usual vasodilatory effect 
of insulin mediated through increased synthesis of nitric oxide 
which normally counters the multiple pressure effect of insulin. 
(Cardillo C, Killcoyne CM, Nambi S, et al 1998) These 
pressor effects, in addition to activation of sympathetic activity, 
include a trophic actions on vascular hypertrophy, increased renal 
sodium reabsorption and structural - changes in the myocardium. 
The failure of vasodilatation to antagonize the multiple 
pressure effects of insulin presumably eventuates in rise in blood 
pressure that may be either a primary cause of hypertension or at 
least a secondary potentiator. 
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d) Endothelial cell dysfunction: 
The impairment of normal vasodilatation in the insulin 
resistance syndrome has been shown to involve failure to 
synthesize the normal endothelium derived relaxing factor (NO). 
Nitric Oxide: 
Hypertensive patients have been shown to have a reduced 
vasodilatory response to various stimuli of NO release that appears 
to be independent of the etiology of the hypertension and the degree 
of the gross vascular structural alteration. Impaired NO mediated 
vasodilatation may promote abnormal vascular remodelling and 
may be involved in the greater propensity for vascular damage in 
blacks than in whites. NO - mediated forearm responsiveness has 
been restored by normalization of blood pressure by anti 
hypertensive drugs with different modes of actions. 
Endothelin: 
Endothelin - 1 causes pronounced and prolonged vaso 
constriction and because inhibitors of its synthesis or binding cause 
significant vasodilatation. (Cardillo C, Killcyone CM, WaclawillM, 
et al 1999). 
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e) Minerals: 
Excess of lead and changing ratios among dietary sodium, 
potassium, calcium and magnesium have also been postulated in 
pathogenesis of primary HT. (Ascherio A, Hennekens C, Willet WC et al 
1998) 
II. Renal retention of excess dietary sodium: 
To induce hypertension, some of the excess sodium must be 
retained by the kidneys. Such retention could arise in a number of ways. 
1) Nephron hetrogeneity: which is hypothesized by Sealey and 
co-workers as the presence of "a sub population of nephrons 
that is ischemic either from afferent arteriolar 
vasoconstriction or from an intrinsic narrowing of the lumen. 
Renin secretion from this sub group of nephrons is tonically 
elevated. This increased renin secretion then  interferes with 
the compensatory capacity of intermingled normal nephrons 
to adaptively excrete sodium and consequently, over all blood 
pressure homeostasis. (Sealey JE, Blumenfeld, Bell GM et al 
1988). 
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2) An acquired inhibitors of the sodium pump (or) other 
abnormalities in sodium transport. 
3) Deficient responsiveness to atrial natriuretic hormones. 
(Richards AM, 1998) 
4) Decreased potassium intake as a contributor to the excess no 
of cases of hypertension found in people of low S.E.S. 
5) A decrease in filtration surface by a congenital or acquired 
deficiency  in  nephron  number or function. 
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Proteinuria 
Physiology: 
Upper limit of normal total urine protein excretion is 150 to 
200mg/ day for adults.  
The upper limit of normal albumin excretion is usually given 
as 30mg/ dl. (Shihabi ZK et al ,1991). 
A very small amount of protein that normally appears in the 
urine is the result of normal tubular secretion. Tamm-Harsfal 
protein is an HMW glycoprotein that is formed in the thick 
ascending  loop of the Henle &   early  DCT. 
Normally large quantities of large high molecular weight 
(HMW) plasma proteins traverse the glomerular capillaries, 
mesangium or both without entering the urinary space. The normal 
glomerular endothelial cell forms a barrier composed of pores of 
100nm that hold back blood cells but other little impediment to 
passage  of  most  proteins. 
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Both charge and size selective properties of the capillary wall 
prevent all large plasma proteins from crossing. LMW proteins are 
normally reabsorbed by the proximal tubule. Thus proteins such as 
alpha2 microglobulin, apoproteins, enzymes, and peptide hormones 
are normally excreted only very small amounts in urine. The 
proteins secreted by tubules are Tamm-Harsfall, IgA and 
urokinase.(Silkensen, JR et al, 2004) 
Pathophysiology: 
Abnormal amount of proteins may appear in urine as the 
result of three mechanisms. 
1) A disruption of the capillary wall barrier may lead to a large 
amounts of HMW plasma proteins that over whelm the 
limited capacity of tubular reabsorption and cause which is 
called of glomerular proteinuria. 
2) Tubular damage/ Dysfunction can inhibit the normal 
response capacity of PCT resulting in  incread amounts of 
mostly LMW proteins to appear in the urine, that is called 
as tubular proteinuria. 
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3) Increased production of normal (or) abnormal plasma 
proteins can be filtered at the glomerular and over helms the 
responsive capacity of PCT. 
 In some diseases like minimal change disease, there is a 
fusion of glomerular epithelial cell foot processes resulting 
in “selective” loss of albumin. Other glomerular diseases 
like in immune-complex deposition there is disruption of 
basement memrane and slit diaphragms resulting in losses 
of albumin and other plasma proteins. The fusion of foot 
processes causes increased pressure across the capillary 
basement memrane resulting in areas with larger pore sizes. 
The combination of increased pressure and larger pores 
results in significant (Nonselective) proteinuria. 
Definition of Abnormal Albumin Excretion 
Category 
24 hrs 
collection 
mg/24min 
Timed 
collection 
(μ/min) 
Spot collection 
(mg/g of 
creatinine) 
Normal < 30 < 20 < 30 
Micro 
albumin 
30 – 299 20- 199 30 – 299 
Clinical 
albuminuria 
> 300 > 200 > 300 
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Urine Albumin Concentration can be Quantified by a Number 
of Assays Including 
1. Radio- immunoassay 
2. Immunotubimetric technique- Depends on the turbidity of 
a solution when albumin in a sample of urine reacts with a 
specific antibody. The turbidity is measured with a 
spectrophotometer and the absorbency is propotional to the 
albumin concentration. (Harmoinen H et al, 1987). 
3. When albumin in the urine sample react with a specific 
antibody, it forms light scattering antigen-antibody 
complexes that can be measured with a laser naphelometer. 
The amount of albumin is propotional to scatter in the 
signal. 
4. Competitive ELISA 
5. High performance liquid chromatography (HPLC) 
The ACR did not provide any advantage in terms of positive 
or negative prediction and required a higher laboratory 
effort.Microalbumin measurement alone is the most convenient 
screening method in daily clinical practice (Ulla Derhaschnig et al, 2002). 
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Micro Albuminuria 
Viberty and Co workers coined the term microalbuminuria to 
indicate increased urine albumin excretion rates in patients with 
normal urine total protein. (Viberti GC et al 1982.) 
Micro albuminuria is defined as 
1) Urine Albumin excretion of 30 to 300mg/ day (Abid D et al, 
1984) 
2) 20 to 200mg/ g of Creatinine in males and 30 to 300mg / gm 
of Creatinine in females. (Mattix  HJ et al 2002)s 
3) ACR – 2.0 – 20 mg/ mmol in men, 2.8- 28mg/mmol in women. 
In patients with primary hypertension, increased urine 
albumin exertion ratio is associated with increased cardio vascular 
morbidity. 
In a study of >11,000 non diabetic hypertensives, the 
presence of micro albuminuria was associated with significantly 
higher prevalence of LVH, CAD, MI, Hyperlipidemia and 
peripheral vascular disease (Agrawal B et a1 ,1996). 
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These is a link between the hypertensive heart disease and 
changes in glomerlar hemodynamic profile in primary hypertension. 
Patients with hypertension and LVH have higher GFR and filtration 
fraction than those without ventricular hypertrophy. Glomerular 
hyperfiltration in patients with HTN is related to cardiac 
remodeling and perhaps, more generalized vascular adaptation. 
Pathophysiology 
It has been hypothesized that microalbuminuria reflects 
diffuse endothelial dysfunction (Pedrinelli R et al, 1994), leading to 
generalized transendothelial sieving of albumin. (Jensen JS et al 
1995). It is likely that MA emerges later in the atherosclerotic 
process (Agewall S et al, 1995). 
Mechanism of function of microalbuminuria in patients with 
primary hypertension. 
1) Increased transglomerular passage of albumin due to 
hyperfiltration. 
2) Glomerular basement membrane abnormalities  
3) Endothelial dysfunction  
4) Nephrosclerosis 
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Measurement of MA is in some guidelines recommended for 
risk stratification in people with HTN. 
(2003 European society of hypertension – European society of 
cardiology guidelines for the management of arterial HTN.  2003). 
Significance of Microalbuminuria 
1) An indicator of subclinical cardiovascular disease. 
2) Marker of vascular endothelial dysfunction. 
3) An important prognostic marker for kidney disease in 
hypertension and Diabetes Mellitus 
4) A risk factor for venous thromboembolism 
5) Increasing microalbuminuria during first 48 hours after 
admission to an ICU predicts elevated risk for acute 
respiratory failure, multi- organ failure and over all mortality. 
Hypertensive Retinopathy 
The retinal circulation undergoes a series of 
pathophysiological changes in response to elevated BP. These 
charges are manifested as a spectrum of signs commonly referred to 
as hypertensive retinopathy. The significance of hypertensive 
retinopathy signs as risk indicators of systemic morbidity and 
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mortality has long been recognized. The JNC VII guidelines 
emphasize that hypertensive retinopathy, together with LVH, renal 
impairment may be considered as indicator of TOD, suggesting that 
physicians should consider a more aggressive approach in 
managing these patients. 
The traditional classification of HTR, dating back to 1939 
was based on work by Keith et al. The classification and its 
modifications typically consists of four grades of hypertensive 
retinopathy with increasing severity. 
Grade-I: “Mild” generalized retinal arteriolar narrowing. 
Grade-II: “more severe” Generalized narrowing with focal 
areas of anteriovenous nicking. 
Grade-III: Above findings with presence of retinal 
haemorrhages, microaneurysms, hard exudates and cotton wool 
spots. 
Grade-IV: Above findings with optic disc swelling and 
macular oedema. 
 26
Left Ventricular Hypertrophy: 
In Hypertension,   Left Ventricle undergoes hypertrophy as a 
compensatory mechanism to reduce wall stress and maintain pump 
function in the face of the increased after load. 
 LVH is an important, independent  predictor of mortality and 
morbidity.[ Levy et al 1990 ] 
At which point LV mass cease to be compensatory and 
becomes deleterious in hypertension is not known, but the concept 
of inappropriate 
LV mass or excess mass beyond that predicted based on 
gender, body weight and haemodynamic burden has been 
introduced to better address this issue. 
Patients with LV hypertrophy are more likely to exhibit 
kidney damage, and increased carotid intima media 
thickness.[Cushman et al 2003]  
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The risk of target organ damage can be further stratified by 
LV geometric pattern; the risk being highest with concentric 
and  intermediate with eccentric hypertrophy. [Devereux et al ] 
Concentric remodelling as well, is an independent predictor 
of increased cardiovascular risk in hypertensive patients. [Ciucci et 
al 1995]. 
 Concentric LV hypertrophy is associated with the greatest 
renal dysfunction and is likely to potentiate the decline in 
glomerular filtration  rate  with  aging.  
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MATERIALS AND METHODS 
Setting        :  hypertension clinic (OPD) and medical wards 
where the patients admitted with problems related 
to hypertension ,Madras medical college& Govt. 
general hospital, Chennai-3 
Collaborating  Department: Department of Bio-Chemistry, 
Madras Medical College,  
Chennai – 600 003 
Design of the Study : Cross Sectional Cohart Study 
Period of the Study :  9 months From Feb 2010 to 
October 2010 
Ethical Clearance :  Obtained 
Consent :  Informed consent from all patients 
and controls 
External Financial support :  Nil 
Conflict of Interest :  Nil 
Analysis  : Date analysed using statistical 
package  - SPSS Software 
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Inclusion Criteria: 
Patients with primary hypertension attending Hypertension 
clinic  and those who admitted to the medical wards with HT 
related problems. 
Exclusion Criteria: 
1) Proven cases of secondary hypertension 
2) Pregnant women 
3) Diabetes Mellitus 
4) Established cases of kidney diseases 
5) UTI 
6) Established macroproteinuria 
7) strenous exercise 
8) CCF 
9) With acute febrile illnesses 
10) History of  NSAID  intake 
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Section of Study Subjects and Controls:            
80 patients with Primary Hypertension (46 males and 34 
females) with mean age 52.53+/-6.8 who were attending 
hypertension clinic and who were admitted in the medical wards of 
MMC, GGH for the period of 9 months from Feb 2010 to October 
2010, formed the study group (cases). 
The control group comprised of normotensive individuals  
(18 males and 22 Females) who were attendants of the study group. 
Each participant was interviewed and examined indetail.  The 
BP of each participant  was measured according to JNC VII 
guidelines with a standardized calibrated measuring  column type  
sphygmomanometer with an appropriate cuff encircling at least 
80% of the arm and in the seated posture , with the feet on the floor 
and arm supposed at heart level (except in stroke patients). BP 
above 140/90 mm of Hg was regarded as Hypertension (JNC VII). 
A detailed case record was prepared for each patient on a 
preformed study sheet.  Detailed history taking and physical 
examination were performed on each patient that specifically 
emphasized on the assessment of the neurological status, 
cardiovascular status and optic fundus.  Optic fundus was examined 
with direct Opthalmoscope. 
 31
Special investigations done: 
In addition to the routine investigations like hematological 
and biochemical profile and work-up for secondary hypertension.  
The following special investigations were done  
1) Fasting Lipid Profile  
The patients were asked to fast for twelve hours prior to the 
blood sample is withdrawn. The lipid profile results were analysed 
on the basis of ATP-3 quidelines of the NECP 
2) ECG: To screen for the evidence of LVH.  
 Sokolow – Lyon Index: 
S in V1 + R in V5 or  V6 more than 35mm 
R in aVL  more than 11mm 
3) Chest Radiography: for cardiothoracic ratio 
4) Computed tomography of the brain for all patients admitted 
with a clinical diagnosis of stroke (5 patients had stroke and 
all of them had MCA Territory Infarction) 
 32
5) Microalbumunuria: was assessed by Turbidimetric  
Immunoassay.  5ml of randomly voided / spot simple was 
used.  In women urine examinations were done during non-
menstrual phase of their cycles.   
The kit used was FIMEMOO25, Erba Mannheim: The 
measuing range was in between 0 and 400mg/L.  The values 
between 25 to 400ml/L was taken  as positive for 
microalbuminuria. 
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Fig-1: Prevalence of microalbinuria in patients of different 
age groups with hypertension
OBSERVATION AND RESULTS  
In our study 80 primary hypertensives were matched with 40 
control populations for microalbuminuria. 
In the study population the age group ranges from 52.16 + 9.4. 
In the control population age group ranges from 52.53 + 6.8. 
Table – 1: Age Distribution in cases and control 
 Group N Mean Std. Deviation 
Std. Error 
Mean 
P 
Value
Age in 
years 
Control 40 52.53 6.809 1.077 
0.829 
  Cases 80 52.16 9.458 1.057 
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Table- 2: Sex distribution in cases and control 
  
Group 
Total P Value
Control Cases
Sex Male Count 18 46 64 
0.196 
    % within Sex 28.1% 71.9% 100.0% 
    % within 
Group 45.0% 57.5% 53.3% 
  Female Count 22 34 56 
    % within Sex 39.3% 60.7% 100.0% 
    % within 
Group 55.0% 42.5% 46.7% 
 
Fig-2: Prevalence of Microalbuminuria in hypertension 
among different sex groups
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Table – 3: Prevalence of microalbinuria in patients of different 
age groups with hypertension. 
Age Group No. of Cases 
Microalbuminuria 
Present P Value 
No % 
< 40 12 0 0% 
0.009 
41- 50 23 7 30.4% 
51-60 31 15 48.4% 
> 60 14 8% 57% 
Total 80 30 37.5% 
Prevalence of MA among hypertensives increased steadily 
with the advancing age as shown in the table (P value 0 .009). 
Fig-3: Prevalence of MA according to their duration of 
Hypertension
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Table–4: Prevalence of Microalbuminuria in hypertension among 
different sex groups  
 
Sex No. of Cases 
Microalbuminuria 
Present P Value 
No % 
Male 46 19 41.3% 
0.414 Female 34 11 32.4% 
Total 80 30 37.5% 
There was no statistically significant difference in the risk for 
MA between the two sex groups (P value 0.414). 
30
6
50
24
0
10
20
30
40
50
Stage- I Stage- 2
Fig-4: Prevalence of MA according to the stage of the 
hypertension
Tota Cases MA Present
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Table- 5: Prevalence of MA according to their duration of 
Hypertension 
 
Duration of disease No. of Cases 
Microalbuminuria 
Present 
No % 
New  15 3 20% 
1-5 years 33 11 33.3% 
6-10 years 124 10 41.7% 
Above 10 years 8 6 75% 
Prevalence of MA is more while the duration of disease 
increases. 
80
39
25
80
25 17
80
5 5
0
20
40
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80
LVH Retinopathy Stroke
Fig-5: Prevalence of MA in hypertensive patients with 
target organ damage and the risk for the development of 
TOD
Total TOD MA
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Table – 6: Prevalence of MA according to the stage of the 
hypertension 
 
Stage of 
Hypertension 
No. of 
Cases 
Microalbuminuria 
Present 
P 
Value 
No % 
Stage- 1 30 6 20% 
0.012 
Stage - 2 50 24 48% 
There was statistically significant difference among the two 
stages of hypertension with MA (P value 0.012). 
 
Table-7: Prevalence of MA in hypertension patients among 
different treatment groups 
 
Treatment 
Groups No. of Cases 
Microalbuminuria 
P Value 
No % 
New cases 15 3 20% 
< 0.001 Regular 37 8 21.6% 
Irregular 28 19 67.9% 
MA is present significantly higher in irregular treatment 
group cases (P<0.001). 
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Table- 8: Prevalence of Microalbuminuria in patients with 
hypertension when compared with total cholesterol level 
 
  
Micro 
albuminuria Total P Value
Positive Negative 
Total 
Cholesterol 
mg% 
Below 
240 
Count 
17 41 58 
0.014
    % within 
Total 
Cholesterol 
<240 mg% 
29.3% 70.7% 100.0% 
    % within 
Micro 
albuminuria
56.7% 82.0% 72.5% 
  Above 
240 
Count 13 9 22 
    % within 
Total 
Cholesterol 
>240mg% 
59.1% 40.9% 100.0% 
    % within 
Micro 
albuminuria
43.3% 18.0% 27.5% 
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Table–9: Prevalence of Microalbuminuria in patients with 
hypertension when compared with different triglycerate levels 
 
  
Micro 
albuminuria Total P Value
Positive Negative
TGL 
mg% 
Below 
200 
Count 27 49  
0.112
% within TGL 
<200mg% 35.5% 64.5% 100.0% 
% within 
Micro 
albuminuria 
90.0% 98.0% 95.0% 
Above 
200 
Count 3 1 4 
% within TGL 
>200mg% 75.0% 25.0% 100.0% 
% within 
Micro 
albuminuria 
10.0% 2.0% 5.0% 
 
Among 4 patients with high trigyceride levels MA was 
detected in 3 (75%) and MA was detected in 27 of 76 patients 
(35.5%) with trigycerides levels of <200mg% which was 
statistically insignificant (P value 0.112). 
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Table – 10: Prevalence of Microalbuminuria in patients with 
hypertension when compared with different HDL Cholesterol 
levels 
 
  
Micro 
albuminuria 
Total P Value
Positive Negative
HDL 
mg% 
Below 
40 
Count 13 8 21 
0.007
% within HDL 
<40mg% 61.9% 38.1% 100.0% 
% within 
Micro 
albuminuria 
43.3% 16.0% 26.3% 
Above 
40 
Count 17 42 59 
% within HDL 
>40mg% 28.8% 71.2% 100.0% 
% within 
Micro 
albuminuria 
56.7% 84.0% 73.8% 
In this study the cases with HDL level of <40mg% were 21 
cases and MA was detected in 13 patients (61.9%) but patients with 
HDL level of >40mg% were 59 and MA was detected in 17 cases 
(28.8%) and the difference was found to be statistically significant. 
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Table- 11: Prevalence of MA in hypertensive patients with target 
organ damage and the risk for the development of TOD 
 
TOD 
Cases MA Present
P Value OR (95% CI) 
No % No % 
LVH 39 48.8% 25 64.1% < 0.001 27.14 (8.8-82.9)
Retinopathy 25 31.3% 17 68% < 0.001 13.4 (4.8–3.73) 
Stroke 5 6.3% 5 100% <0.001 4.6 (3.2-6.5) 
Among 80 cases, thrombotic stroke was found in 5 (6.3%) 
and the MA was detected in all cases that was statistically 
significant. 
Among the hypertensive patients LVH was present in 39 
(48.8%) cases and the MA was detected in 25(64.1) cases which 
was statistically significant. Hypertensive retinopathy was noted in 
25(31.3%) cases among which MA was demonstrated in 17(68%) 
which is statistically significant (P value <0.01). 
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DISCUSSION 
In our study, there were 80 patients with 40 control subjects 
compared.  The mean age of study patients were 52.16 +/- 9.4 and 
in control were 52.53 +/- 6.8 and P value is (0.829).  So almost 
same age groups were selected.   
Among 80 patients 46 were male and 34 were females and in 
control population males were 19 and females were 22 and P value 
was 0.16 (> 0.05).  Sex groups were also not statistically 
significant. 
The overall presence of micro albuminuria in primary 
hypertension is 37.5% which is higher than the prevalence observed 
in Life study (23%) (Wachtell K el al, 2002).  So our observation 
on high prevalence of MA in patients with primary hypertension 
must alert the clinicians regarding the high prevalence of 
subclinical CKD in this part of the world especially in view of 
observations made by Mani MK from south India (ManiMK et al, 
2009) on the strategies for reduction of the burden of CKD by early 
detection and treatment for hypertension.  
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It was observed the prevalence of MA among primary 
hypertensives (increased steadily with the advancing age (P value – 
0.009 significant).  This finding is comparable with that of the 
study conducted by Hitha B  et al, 2008.  So advancing age is found 
to be a risk factor for higher prevalence of MA in our study also as 
observed.  (Tsioutis et al 2005).   
 There was no statistically significant difference in the 
prevalence of MA among males and females hypertensives.  (P 
value 0.414) 
 It was observed  that  prevalence of  MA  steadily increased 
according to their duration of the disease. 
There was statistically significant difference among the two 
stages of hypertension with microalbuminuria (P=0.012).The 
prevalence  is more with stage 2 Hypertensive (P Value 0.012) 
The prevalence of MA in patient with regular treatment 
was lesser when compared with patients on irregular treatment.  
So strict round the clock control of high BP is important  in 
reducing the risk of MA in hypertensives because even isolated 
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ambulatory hypertension is associated with higher risk for TOD 
(Torun D et al, 2009). 
Prevalence of MA in patient with primary hypertension with 
unfavourable Lipid Profile is more when compared to patients with  
favourable lipid profile.   
In patients with hypertension, LVH is one of the earliest TOD 
like MA (Messerli fit et al 2001) and there is a significant 
association between these two subtle TOD’s as shows in many 
studies. 
The prevalence of LVH found in our world was 48.8% 
through the prevalence of LVH reported in other studies was low.  
The prevalence of LVH according to Hitha  B et al was 29.33% 
But the higher the odds for LVH in cases with MA 
(OR=27.14) implies higher risk for cardiovascular events in the 
study population with hypertension.   
Early screening of hypertensive patients for MA and 
aggressive management of positive cases with drugs that reduce 
MA, might reduce their higher risk, for progression to severe CKD 
 46
and adverse cardiovascular outcomes as shows in many studies 
(Assadi F et al, 2001, Amold JM et al ,2003) 
MA had been reported to be three times more prevalent in 
patients with recent stroke (Beamer NB at al, 1999) and the risk for 
the future stroke had been found to be high among patients with 
MA.  (Wachtell K et al, 2003).  MA was more prevalent among 
patients with stroke (OR=4.6) in the present study as well. 
The prevalence of MA was also higher among those with 
hypertensive  retinopathy in our study.  (P < 0.001). 
The risk for the development of retinopathy in patients with 
primary hypertension and microalbuminuria is higher (OR 13.4). 
Several studies have indicated that the presence of MA is a 
independent predictor of cardiovascular morbidity and mortality in 
patients with primary hypertension (Jalal S et al, 2001). Our study 
also shows that microalbuminuria is more prevalent in primary 
hypertensives with TOD. 
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CONCLUSION 
The following conclusions were derived from our study, 
 Prevalence of microalbuminuria is common primary 
hypertensives and is around 37.5%. 
 Patients with advanced age and longer duration of 
hypertension  develop MA. 
 Sex differences do not pose any significant risk for the 
developmentof microalbuminuria. 
 There is a possible correlation between the severity of 
hypertension and microalbuminuria. 
 Prevalence of MA is more in Patients with primary 
hypertension in the presence of unfavourable lipid 
profile. 
 These is higher risk of development of TOD in patients 
with microalbuminuria among primary hypertension. 
 Prompt and adequate control of BP delays progression to 
TOD in patients with MA and hence a more aggressive 
approach is required in hypertension with MA. 
 48
SUMMARY 
Primary hypertension is a major health problem through out 
the world causing coronary, cerebral and renal vascular disease. 
Our study shows that the prevalence of microalbuminuria in 
patients with primary hypertension is 37.5% and has a positive 
correlation with the severity of hypertension and thus may be an 
early marker for end organ damage susceptibility. This study 
implies that early screening of primary hypertension of MA and 
prompt treatment of positive cases might reduce the disease burden 
related to severe CKD, cardiovascular events in the community. 
S.No Name Age Sex yrs Stage of HTN TREATMENT
Total 
Cholesterol 
mg%
TGL mg% HDL mg% Micro albuminuria ECG- LVH Echo-LVH Retinopathy
1 subramani 60 M 7 2 REGULAR 210 168 54 - + + II
2 EGAMBARAM 62 M 4 2 IRREGULAR 198 208 48 POSITIVE + + II
3 RANI 60 F NEW 2 N K 257 152 48 POSITIVE + - -
4 SUGANTHI 51 F 2 1 REGULAR 186 120 38 - + + -
5 POOSAMMAL 59 F 1 2 REGULAR 256 182 40 - + + +
6 GNANAM 41 F 1 1 REGULAR 228 156 54 - - - -
7 BALAKRISHNAN 55 M 12 2 IRREGULAR 258 158 46 POSITIVE - + -
8 KAMALA 50 F 4 1 REGULAR 220 150 40 - - - -
9 SELVI 40 F 3 1 REGULAR 250 152 46 - - - -
10 RAMASAMI 62 M 10 2 IRREGULAR 189 143 51 POSITIVE + + +
11 BALU 41 M 4 2 REGULAR 257 152 48 - - - -
12 CHITRABABU 56 F 6 1 REGULAR 252 143 48 - - - -
13 ABDUL RAHMAN 70 M 15 2 IRREGULAR 184 105 41 - - + -
14 SYED KHADAR 78 M 14 1 REGULAR 200 120 40 POSITIVE + + +
15 SUBBAN 62 M 10 2 IRREGULAR 200 156 41 - + + +
16 VELU 42 M NEW 2 N K 198 141 54 - - - -
17 KUPPUSAMY 39 M NEW 1 N K 221 176 51 - - - -
18 SARASU 36 F NEW 2 N K 287 134 41 - - - -
19 VISALATCHI 62 F 8 2 IRREGULAR 200 129 57 POSITIVE + + +
S.No Name Age Sex yrs Stage of HTN TREATMENT
Total 
Cholesterol 
mg%
TGL mg% HDL mg% Micro albuminuria ECG- LVH Echo-LVH Retinopathy
20 MANI 42 M 2 2 REGULAR 233 159 44 POSITIVE + - +
21 KRISHNAN 62 M 12 1 REGULAR 174 110 41 - + + -
22 PARTHASARATHY 60 M 6 2 REGULAR 199 109 43 - - + -
23 SRINIVASAN 51 M 5 2 IRREGULAR 200 140 51 POSITIVE + + -
24 SATHYANESAN 44 M 3 1 REGULAR 196 94 58 - - - -
25 ALAGAPPAN 39 M NEW 2 N K 210 99 53 - - - -
26 THANGAMMAL 39 F NEW 2 N K 200 161 42 - - - -
27 SUBBURAJ 59 M 9 2 IRREGULAR 298 200 40 POSITIVE + + +
28 KANTHA 49 F NEW 2 N K 199 113 40 - - - -
29 SUMATHY 41 F 3 2 REGULAR 221 132 49 - - - -
30 VASANTHA 50 F 8 1 REGULAR 183 105 50 - - - -
31 AMUTHA 40 F 7 2 IRREGULAR 211 144 41 - - - -
32 AYYAVU 53 M 6 2 REGULAR 192 106 50 - + + +
33 GOVINDHAN 60 M 14 2 IRREGULAR 280 196 40 POSITIVE + + +
34 SARATHAMBAL 55 F 8 1 REGULAR 197 139 45 - - - -
35 SEETHA 60 F 9 2 IRREGULAR 281 188 43 POSITIVE + + +
36 GURUMOORTHY 39 M NEW 1 N K 210 98 53 - - - -
37 SANTHANAM 55 M 4 2 REGULAR 185 100 50 POSITIVE - - -
38 SABESAN 40 M 1 2 IRREGULAR 284 199 46 - - - -
39 NALINI 41 F 2 1 REGULAR 187 115 49 - - - -
S.No Name Age Sex yrs Stage of HTN TREATMENT
Total 
Cholesterol 
mg%
TGL mg% HDL mg% Micro albuminuria ECG- LVH Echo-LVH Retinopathy
40 SIVAMOORTHY 56 M 1 2 REGULAR 174 108 50 - - - -
41 KAMALAMMAL 65 F 2 2 IRREGULAR 304 200 38 POSITIVE + + +
42 PALANISAMY 51 M NEW 1 N K 197 142 49 - - - -
43 SUBATHRA 40 F 1 2 REGULAR 201 140 51 - - - -
44 CHELLAMMAL 59 F 3 1 IRREGULAR 184 205 50 - - - -
45 SUNDARAM 59 M 7 2 REGULAR 281 193 50 POSITIVE + + +
46 SAVARTMUTHU 50 M 3 2 IRREGULAR 206 186 50 POSITIVE + + -
47 LILLY 43 F NEW 2 N K 210 142 56 - - - -
48 JOSEPH 50 M 4 2 IRREGULAR 180 147 56 - + + +
49 VENI 42 F 1 2 REGULAR 174 192 52 - - - -
50 VALARMATHY 59 F 11 2 IRREGULAR 199 104 41 POSITIVE + - +
51` VARATHARAJAN 51 M 8 1 IRREGULAR 198 280 40 POSITIVE - + -
52 PERIASAMY 61 M 6 1 REGULAR 162 141 42 - + + +
53 DURAISAMY 49 M NEW 2 N K 210 132 59 - + - -
54 SOUNDARAM 49 F 9 2 IRREGULAR 256 200 38 POSITIVE - + +
55 ANDAPPAN 60 M 4 2 REGULAR 211 192 41 POSITIVE + + +
56 MARY 57 F NEW 2 N K 300 199 42 POSITIVE + + +
57 VEERAMUTHU 60 M 6 1 REGULAR 188 123 42 - - - -
58 SARASWATHYAMMAL 59 F 10 2 REGULAR 152 141 39 - + + +
59 ESWARAN 40 M 1 2 REGULAR 180 140 52 - - - -
S.No Name Age Sex yrs Stage of HTN TREATMENT
Total 
Cholesterol 
mg%
TGL mg% HDL mg% Micro albuminuria ECG- LVH Echo-LVH Retinopathy
60 PRAKASAM 42 M 4 2 IRREGULAR 206 166 40 POSITIVE + - -
61 MANI 51 M NEW 2 N K 199 140 43 POSITIVE - + -
62 MUTHUSAMY 49 M 4 1 REGULAR 271 200 40 POSITIVE + + +
63 KALPANA 50 F 2 2 IRREGULAR 244 154 40 POSITIVE + - -
64 KANAGAM 49 F 1 1 REGULAR 174 162 49 - - + -
65 SWAMINATHAN 39 M 1 1 REGULAR 202 140 52 - - - -
66 KESAVAN 41 M NEW 2 N K 182 146 50 - - - -
67 MEENAKSHI 61 F 4 1 REGULAR 174 151 49
68 SRIRAM 38 M NEW 1 N K 199 141 50 - - - -
69 KRISHNAVENI 68 F 20 2 IRREGULAR 195 124 39 POSITIVE + + -
70 RUCKMANI 57 F 3 2 IRREGULAR 200 142 51 - - + -
71 RAMAKRISHNAN 70 M 9 1 REGULAR 187 122 40 POSITIVE + + +
72 LAKSHMIAMMAL 61 F 11 2 IRREGULAR 241 183 41 POSITIVE + + -
73 NAGALAXMI 43 F 4 1 REGULAR 284 195 40 - + - +
74 RANGACHARI 70 M 6 1 REGULAR 195 - - - - - -
75 LOGANATHAN 52 M 1 2 REGULAR 270 150 41 - + + -
76 SUNDARI 52 F 6 1 REGULAR 184 174 38 POSITIVE + - +
77 GANAPATHY 49 M 8 2 IRREGULAR 287 210 40 POSITIVE + + -
78 VADIVEL 51 M 5 1 IRREGULAR 170 107 46 POSITIVE + - -
79 RAMARAO 60 M 8 1 IRREGULAR 218 173 40 - + + -
S.No Name Age Sex yrs Stage of HTN TREATMENT
Total 
Cholesterol 
mg%
TGL mg% HDL mg% Micro albuminuria ECG- LVH Echo-LVH Retinopathy
80 RAJARAM 55 M 10 1 IRREGULAR 253 184 40 - + + -
81 GOMATHY 40 F C0NTROL C C 180 100 51 - - - -
82 JEYA 55 F C0NTROL C C 201 148 51 - - - -
83 SULOCHANA 48 F C0NTROL C C 170 154 49 - - - -
84 CHELLAMMAL 49 F C0NTROL C C 198 142 48 - - - -
85 POONGOTHAI 59 F C0NTROL C C 160 170 48 - - - -
86 SELVARAJ 60 M C0NTROL C C 174 147 51 - - - -
87 PALANI 42 M C0NTROL C C 139 159 56 - - - -
88 MANIVEL 59 M C0NTROL C C 208 169 46 - - - -
89 TAMILSELVAM 51 M C0NTROL C C 236 136 51 - - - -
90 KRISHNAN 62 M C0NTROL C C 162 191 50 - - - -
91 SYEDFATHIMA 67 F C0NTROL C C 210 150 48 - - - -
92 PONNAMMAL 57 F C0NTROL C C 154 141 43 - - - -
93 SAROJAMMAL 60 F C0NTROL C C 99 105 40 - - - -
94 PAPPU 59 F C0NTROL C C 181 141 43 - - - -
95 MEENAKSHIAMMAL 50 F C0NTROL C C 160 112 42 - - - -
96 VELANKANNI 49 F C0NTROL C C 173 142 49 - - - -
97 TARA 40 F C0NTROL C C 199 171 52 - - - -
98 RAMAN 57 M C0NTROL C C 184 144 51 - - - -
99 THANGARAJ 52 M C0NTROL C C 174 151 47 - - - -
S.No Name Age Sex yrs Stage of HTN TREATMENT
Total 
Cholesterol 
mg%
TGL mg% HDL mg% Micro albuminuria ECG- LVH Echo-LVH Retinopathy
100 MURUGESAN 54 M C0NTROL C C 141 172 42 - - - -
101 PANDI 64 M C0NTROL C C 185 171 41 - - - -
102 MUTHUMANICKAM 61 M C0NTROL C C 147 123 51 - - - -
103 RAJASEKAR 49 M C0NTROL C C 188 150 46 - - - -
104 MANIKANDAN 40 M C0NTROL C C 197 141 49 - - - -
105 RAJADURAI 55 M C0NTROL C C 200 149 50 - - - -
106 AMAMMANIAMMAL 59 F C0NTROL C C 168 98 41 - - - -
107 MALATHY 49 F C0NTROL C C 199 89 54 - - - -
108 LATHA 46 F C0NTROL C C 142 111 41 - - - -
109 KAMARAJ 51 M C0NTROL C C 174 112 51 - - - -
110 VADIVU 49 F C0NTROL C C 188 121 42 - - - -
111 MEIKANDAN 50 M C0NTROL C C 154 141 49 - - - -
112 DIVAKAR 46 M C0NTROL C C 179 140 56 - - - -
113 THIARAJAN 61 M C0NTROL C C 180 154 48 - - - -
114 KANNAN 54 M C0NTROL C C 200 153 51 - - - -
115 MANGAI 56 F C0NTROL C C 210 140 42 - - - -
116 MUTHAMMAL 50 F C0NTROL C C 220 151 40 - - - -
117 KAMATCHI 49 F C0NTROL C C 151 112 39 - - - -
118 MALLIGA 44 F C0NTROL C C 184 154 50 - - - -
119 LEEMA 50 F C0NTROL C C 171 141 50 - - - -
S.No Name Age Sex yrs Stage of HTN TREATMENT
Total 
Cholesterol 
mg%
TGL mg% HDL mg% Micro albuminuria ECG- LVH Echo-LVH Retinopathy
120 DAISY 48 F C0NTROL C C 198 89 41 - - - -
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A STUDY ON BIOCHEMICAL MARKERS IN PRIMARY HYPERTENSION  
IN CORELATION WITH TARGET ORGAN DAMAGE 
Name:           Age:    Sex: 
Address:            Occupation: 
 
Duration of Hypertension: 
SYMPTOMS: 
     Headache       Oliguria       Cold intolerance 
     Giddiness       Puffiness of Face       Weight gain 
     Blurring of vision       Swelling of legs       Hoarseness of voice 
     Epistaxis       Anorexia       Centripetal obesity 
     Chest Pain       Vomiting/Hiccups       Hirsutism 
     Palpitation       Easy fatiguability       Amenorrhea/Menorrhagia 
     Dyspnea       Altered bowel habits       Proximalmuscle weakness 
     Fever       Dysuria       Hypogastric Pain 
     Loin Pain 
PAST HISTORY:          DRUG INTAKE 
     DM       NSAIDS 
     Renal disorders     
     Chronic Liver disorders 
     Thyroid Disorders 
PERSONAL HISTORY: 
     Smoking       Alcoholism       Drug abuse                   STD 
     Prolonged Starvation       Exercise 
FAMILY HISTORY: 
     Hypertension       DM       Chronic kidney disease 
GENERAL EXAMINATION: 
Anthropometry: 
Ht:            cms  Wt:               kgs    BMI: 
Hydration Status    JVP 
FUNDUS:   
 
Features of Thyroid Disorders: 
Features of Cushing’s Syndrome: 
PULSE:    BLOOD PRESSURE: 
    Rt    Lt 
 
                      Stage of Hypertension 
SYSTEMIC EXAMINATION: 
CVS:  RS:  ABDOMEN:    CNS: 
INVESTIGATIONS: 
Hb:              TC:   DC:   P‐     L‐         E‐         M‐  Plt: 
ESR  : 
Blood Glucose Fasting  : 
Blood Urea  : 
Serum Creatinine  : 
Uric Acid  : 
Serum Electrolytes  :  Na+      K+   
LIPID PROFILE: 
Total Cholesterol  :  HDL  : 
Triglycerides  :  LDL  : 
Chol: HDL Ratio  :  VLDL  : 
LIVER FUNCTION TEST: 
Bilirubin Total  : 
               Direct  : 
SGOT  : 
SGPT  : 
Total Protein  : 
         Albumin  : 
         Globulin  : 
Sr. Alkaline Phosphatase  : 
URINE EXAMINATION: 
Micro Albumin  :        Deposits: 
Albumin  : 
Sugar  : 
ECG: 
 
X‐RAY CHEST PA VIEW  : 
 
ECHO CARDIOGRAM  :   
 
USG ABDOMEN  :   
 
 
